1-4 of 4
Rita Campanelli, Biol. Sci
Close
Sort by
Journal Articles

What Is the True Response Rate to Ruxolitinib in Persons with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF) Needing Therapy for Splenomegaly ?

Giovanni Barosi, MD, Valentina Poletto, Biol Sci, Elisa Bonetti, BS, Laura Villani, Biol Sci, Paolo Catarsi, PhD, Gianluca Viarengo, MD, Rita Campanelli, Biol. Sci, Margherita Massa, PhD, Vittorio Rosti, MD
Journal: Blood
Blood (2014) 124 (21): 3191.
https://doi.org/10.1182/blood.V124.21.3191.3191
Published: 2014
Journal Articles

Decrease Of T Regulatory Cells In Patients With Myelofibrosis Receiving Ruxolitinib

Giovanni Barosi, MD, Rita Campanelli, Biol. Sci, Gabriela Fois, Biol. Sci, Valentina Poletto, Biol. Sci, Laura Villani, Biol. Sci, Elisa Bonetti, BS, Paolo Catarsi, PhD, Vittorio Rosti, MD, Margherita Massa, PhD
Journal: Blood
Blood (2013) 122 (21): 4057.
https://doi.org/10.1182/blood.V122.21.4057.4057
Published: 2013
Journal Articles

JAK2 V617F Genotype Is a Strong Determinant of Blast Transformation in Primary Myelofibrosis.

Giovanni Barosi, MD, Valentina Poletto, Biol Sci, Margherita Massa, Ph D, Rita Campanelli, Biol. Sci, Laura Villani, Biol Sci, Elisa Bonetti, Biol Sci, Gianluca Viarengo, MD, Paolo Catarsi, PhD, Catherine Klersy, MD, Vittorio Rosti, MD
Journal: Blood
Blood (2012) 120 (21): 2829.
https://doi.org/10.1182/blood.V120.21.2829.2829
Published: 2012
Journal Articles

Prefibrotic Myelofibrosis (PreMF) Belongs to a Continuum of Epidemiological, Clinical and Histological Characteristics Featuring Primary Myelofibrosis (PMF)

Giovanni Barosi, MD, Vittorio Rosti, MD, Rita Campanelli, Biol. Sci, Paolo Catarsi, PhD, Antonina M. Isgrò, Lab Tech, Letizia Lupo, MD, Margherita Massa, Ph D, Valentina Poletto, Biol Sci, Gianluca Viarengo, MD, Laura Villani, Biol Sci, Umberto Magrini, MD
Journal: Blood
Blood (2011) 118 (21): 1743.
https://doi.org/10.1182/blood.V118.21.1743.1743
Published: 2011